Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens

Nature Medicine

Volumn 15, Issue 5, 2009, Pages 566-571

  Fan, Alice C ^a   Deb Basu, Debabrita ^b   Orban, Mathias W ^a   Gotlib, Jason R ^a   Natkunam, Yasodha ^a   O'Neill, Roger ^b   Padua, Rose Ann ^c   Xu, Liwen ^a   Taketa, Daryl ^b   Shirer, Amy E ^a   Beer, Shelly ^a   Yee, Ada X ^a   Voehringer, David W ^b   Felsher, Dean W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cell Biosciences   (United States)

^c UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CASPASE 3; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MYC PROTEIN; PROTEIN BCL 2; STAT3 PROTEIN; STAT5 PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BURKITT LYMPHOMA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG RESPONSE; ENZYME PHOSPHORYLATION; FOLLICULAR LYMPHOMA; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LYMPHOMA; MOUSE; NANOFLUIDIC PROTEOMIC IMMUNOASSAY; NANOFLUIDICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ASSAY;

BURKITT LYMPHOMA; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; IMMUNOASSAY; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; NEOPLASMS; ONCOGENE PROTEINS; ONCOGENES; PHOSPHOPROTEINS; PROTEIN ISOFORMS; PROTEOMICS;

EID: 67349107068     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.1903     Document Type: Article

References (40)

1. Futreal, P.A. et al. Cancer and genomics. Nature 409, 850-852 (2001).
2. Harris, H. Tumour suppression: putting on the brakes. Nature 427, 201 (2004).
3. Sharpless, N.E. & DePinho, R.A. Cancer: crime and punishment. Nature 436, 636-637 (2005).
4. Vogelstein, B. & Kinzler, K.W. Cancer genes and the pathways they control. Nat. Med. 10, 789-799 (2004).
5. Dalla-Favera, R. et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA 79, 7824-7827 (1982).
6. Ferry, J.A. Burkitt's lymphoma: clinicopathologic features and differential diagnosis. Oncologist 11, 375-383 (2006).
7. Dang, C.V., O'Donnell, K.A. & Juopperi, T. The great MYC escape in tumorigenesis. Cancer Cell 8, 177-178 (2005).
8. Tsujimoto, Y., Cossman, J., Jaffe, E. & Croce, C.M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228, 1440-1443 (1985).
9. Bordeleau, L. & Berinstein, N.L. Molecular diagnostics in follicular non-Hodgkin's lymphoma: a review. Semin. Oncol. 27, 42-52 (2000).
10. Lugo, T.G., Pendergast, A.M., Muller, A.J. & Witte, O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079-1082 (1990).
11. Melo, J.V. & Barnes, D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 7, 441-453 (2007).
12. Weisberg, E., Manley, P.W., Cowan-Jacob, S.W., Hochhaus, A. & Griffin, J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7, 345-356 (2007).
13. Ghaffari, S., Daley, G.Q. & Lodish, H.F. Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays. Leukemia 13, 1200-1206 (1999).
14. Felsher, D.W. Cancer revoked: oncogenes as therapeutic targets. Nat. Rev. Cancer 3, 375-380 (2003).
15. Giuriato, S., Rabin, K., Fan, A.C., Shachaf, C.M. & Felsher, D.W. Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin. Cancer Biol. 14, 3-11 (2004).
16. Druker, B.J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
17. Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652 (2002).
18. Weisberg, E. et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141 (2005).
19. Brozik, A. et al. Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK. Ann. NY Acad. Sci. 1090, 344-354 (2006).
20. Kohmura, K., Miyakawa, Y, Kawai, Y, Ikeda, Y. & Kizaki, M. Different roles of p38 MAPKand ERK in STI571-induced multi-lineage differentiation of K562 cells. J. Cell. Physiol. 198, 370-376 (2004).
21. Solit, D.B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
22. O'Neill, R.A. et al. Isoelectric focusing technology quantifies protein signaling in 25 cells. Proc. Natl. Acad. Sci. USA 103, 16153-16158 (2006).
23. Felsher, D.W. & Bishop, J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199-207 (1999).
24. Karlsson, A. et al. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Bloodl 101, 2797-2803 (2003).
25. Giuriato, S. et al. Sustained regression of tumors upon MYC inactivation requires p53 orthrombospondin-1 to reverse the angiogenic switch. Proc. Natl. Acad. Sci. USA 103, 16266-16271 (2006).
26. Shachaf, CM. et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Bloodl 110, 2674-2684 (2007).
27. Mitani, S., Sugawara, I., Shiku, H. & Mori, S. Expression of c-myc oncogene product and ras family oncogene products in various human malignant lymphomas defined by immunohistochemical techniques. Cancer 62, 2085-2093 (1988).
28. Wennborg, A.D., Altiok, E., Moore, J.P., Ernberg, I. & Klein, G. Differential c-myc protein expression in Burkitt's lymphomas and EBV-transformed lymphoblastoid lines. Eur. J. Cancer 27, 1643-1645 (1991).
29. Johnson, N.A. et al. Prognostic significance of secondary cytogenetic alterations in follicular lymphomas. Genes Chromosom. Cancer 47, 1038-1048 (2008).
30. Hann, S.R. & Eisenman, R.N. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol. Cell. Biol. 4, 2486-2497 (1984).
31. Ramsay, G., Evan, G.I. & Bishop, J.M. The protein encoded by the human proto-oncogene c-myc. Proc. Natl. Acad. Sci. USA 81, 7742-7746 (1984).
32. Barrans, S.L. etal. Germinal center phenotypeand bc l-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Bloodl 99, 1136-1143 (2002).
33. Colomo, L. et al. Clinical impact of the differentiation profile assessed by immuno-phenotyping in patients with diffuse large B-cell lymphoma. Bloodl 101, 78-84 (2003).
34. Gascoyne, R.D. et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Bloodl 90, 244-251 (1997).
35. Calvo, K.R. etal. IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. Bloodl 112, 3818-3826 (2008).
36. Camacho, F.I. et al. Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. Am. J. Surg. Pathol. 27, 762-771 (2003).
37. Dierlamm, J. et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Bloodl 87, 299-307 (1996).
38. Irish, J.M., Czerwinski, D.K., Nolan, G.P. & Levy, R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Bloodl 108, 3135-3142 (2006).
39. Lee, T., Yao, G., Nevins, J. & You, L. Sensingand integration of Erkand PI3Ksignals by Myc. PLOS Comput. Biol. 4, e1000013 (2008).
40. Obenauer, J.C., Cantley, L.C.&Yaffe, M.B. Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 31, 3635-3641 (2003).